Skip to Content
Merck
All Photos(1)

Key Documents

More Documents

Y0000117

Halofantrine hydrochloride

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

1,3-Dichloro-a-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-9-phenanthrenemethanol hydrochloride, Halfan

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C26H30Cl2F3NO · HCl
CAS Number:
36167-63-2
Molecular Weight:
536.88
MDL number:
MFCD00879136
UNSPSC Code:
41116107
PubChem Substance ID:
329830854
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

halofantrine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

Cl.CCCCN(CCCC)CCC(O)c1cc2c(Cl)cc(Cl)cc2c3cc(ccc13)C(F)(F)F

InChI

1S/C26H30Cl2F3NO.ClH/c1-3-5-10-32(11-6-4-2)12-9-25(33)23-16-22-21(14-18(27)15-24(22)28)20-13-17(26(29,30)31)7-8-19(20)23;/h7-8,13-16,25,33H,3-6,9-12H2,1-2H3;1H

InChI key

WANGFTDWOFGECH-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Halofantrine hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Halofantrine is a blocker of delayed rectifier potassium current via the inhibition of hERG channel.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Hazard Statements

H413

Precautionary Statements

P273

Hazard Classifications

Aquatic Chronic 4

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ji-Hyun Lee et al.
PloS one, 7(8), e42573-e42573 (2012-08-21)
Anticancer therapies that target single signal transduction pathways often fail to prevent proliferation of cancer cells because of overlapping functions and cross-talk between different signaling pathways. Recent research has identified that balanced multi-component therapies might be more efficacious than highly
N M Iskander et al.
The Journal of laryngology and otology, 124(10), 1061-1066 (2010-06-12)
Halofantrine is a newly developed antimalarial drug used for the treatment of Plasmodium falciparum malaria. The introduction of this drug has been delayed because of its possible side effects, and due to insufficient studies on adverse reactions in humans. There
Torsten Frosch et al.
Journal of biomedical optics, 15(4), 041516-041516 (2010-08-31)
The structure of the antimalarial drug halofantrine is analyzed by means of density functional theory (DFT) calculations, IR, and Raman spectroscopy. Strong, selective enhancements of the Raman bands of halofantrine at 1621 and 1590 cm(-1) are discovered by means of
Henrik Tønsberg et al.
The Journal of pharmacy and pharmacology, 62(1), 63-70 (2010-08-21)
The aim of this study was to examine the effects of formulations of polysorbate 80 (PS 80) and polyethylene glycol 400 (PEG 400) on the precipitation and oral bioavailability of the hydrophobic drug halofantrine. The in-vitro dilution profile of the
Anthony A Attama et al.
Asian Pacific journal of tropical medicine, 4(4), 253-258 (2011-07-21)
To formulate and evaluate in vitro, surface-modified solid lipid microspheres containing halofantrine using lipid matrix formed from goat fat and a phospholipid (P90H). The model drug, halofantrine in an increasing concentration of 1%, 2%, 3%, 4% and 5% w/w was
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service